Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAP-219 in adult participants with focal seizures
NCT07594119Phase 3Recruiting
- Sponsor
- Rapport Therapeutics
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of RAP-219 in focal epilepsy, sponsored by Rapport Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
RAP-219
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT07594119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594119.